RKDA
Arcadia Biosciences, Inc.
$0.9250
-13.55%
$1.9M
No data for this timeframe.
Vol
Market Cap$1.9M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$27.8K
Inst. Activity0 buys / 1 sells
SEC Reports3
Press Releases1
Recent Activity
May 14, 2026
SEC
Arcadia Biosciences reported Q1 2026 revenue of $1.1M, down 8% YoY from $1.2M, and a net loss of $4.4M ($2.11/share) vs
8-K — Impact 6/10
Apr 30, 2026
SEC
Arcadia Biosciences filed Amendment No. 1 to its 2025 10-K solely to add Part III information (director/officer details,
10-K/A — Impact 5/10
Apr 3, 2026
SEC
Arcadia Biosciences (RKDA) dismissed Deloitte & Touche LLP as its independent auditor and appointed Ramirez Jimenez Inte
8-K — Impact 7/10
Inst.
MORGAN STANLEY — NEAR_EXIT
2 shares ($4.00)
Inst.
UBS Group AG — TRIM
1,099 shares ($3.8K)
May 6, 2026
earnings_calendar
RKDA Q1 2026 Earnings Scheduled — 2026-05-06
Mar 26, 2026
Press
Arcadia Biosciences reported a 4% year-over-year decline in full-year 2025 revenue despite a 17% increase in Zola® cocon
Impact 6/10
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 21, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 23, 2024 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 5, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Aug 28, 2023 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jul 24, 2023 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Latest Reports
BEARISH
8-K
6/10
Arcadia Biosciences reported Q1 2026 revenue of $1.1M, down 8% YoY from $1.2M, and a net loss of $4.4M ($2.11/share) vs
May 14, 2026
NEUTRAL
10-K/A
5/10
Arcadia Biosciences filed Amendment No. 1 to its 2025 10-K solely to add Part III information (director/officer details,
Apr 30, 2026
MIXED
Press
6/10
Arcadia Biosciences reported a 4% year-over-year decline in full-year 2025 revenue despite a 17% increase in Zola® cocon
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $27.8K | — |
| BANK OF AMERICA CORP | $24.00 | — |
| MORGAN STANLEY | $4.00 | NEAR_EXIT |
3 institutional holders with $27.8K total value (14,052 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, MORGAN. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 14,038 | $27.8K | 99.9% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 12 | $24.00 | 0.1% | — |
| 3 | MORGAN STANLEY | 2 | $4.00 | 0.0% | NEAR_EXIT -99.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | NEAR_EXIT | 608 | 2 | -99.7% | $4.00 | 2025-Q4 |
| UBS Group AG | TRIM | 2,544 | 1,099 | -56.8% | $3.8K | 2025-Q3 |
| UBS Group AG | TRIM | 8,560 | 2,544 | -70.3% | $11.0K | 2025-Q2 |
| MORGAN STANLEY | ADD | 608 | 787 | +29.4% | $3.4K | 2025-Q2 |
| UBS Group AG | TRIM | 13,945 | 8,560 | -38.6% | $25.4K | 2025-Q1 |
| UBS Group AG | DOUBLED | 239 | 13,945 | +5734.7% | $82.6K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
BEARISH
8-K
6/10
Arcadia Biosciences reported Q1 2026 revenue of $1.1M, down 8% YoY from $1.2M, and a net loss of $4.
May 14, 2026
NEUTRAL
10-K/A
5/10
Arcadia Biosciences filed Amendment No. 1 to its 2025 10-K solely to add Part III information (direc
Apr 30, 2026
BEARISH
8-K
7/10
Arcadia Biosciences (RKDA) dismissed Deloitte & Touche LLP as its independent auditor and appointed
Apr 3, 2026
Historical analyst distribution (last covering-analyst action Aug 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 21, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 23, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 5, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 28, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jul 24, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 5, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 14, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 6, 2026
earnings_calendar
RKDA Q1 2026 Earnings Scheduled — 2026-05-06
Mar 26, 2026
earnings
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
<p align="center"><strong><em>-- Zola</em></strong><sup><strong><em>®</em></strong></sup><strong><em> revenues increase 17% year-over-year --</em></st
Mar 18, 2026
earnings_calendar
RKDA Q4 2025 Earnings After Market Close — 2026-03-18